238 related articles for article (PubMed ID: 24836440)
1. BCR-ABL affects STAT5A and STAT5B differentially.
Schaller-Schönitz M; Barzan D; Williamson AJ; Griffiths JR; Dallmann I; Battmer K; Ganser A; Whetton AD; Scherr M; Eder M
PLoS One; 2014; 9(5):e97243. PubMed ID: 24836440
[TBL] [Abstract][Full Text] [Related]
2. Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia.
Kollmann S; Grundschober E; Maurer B; Warsch W; Grausenburger R; Edlinger L; Huuhtanen J; Lagger S; Hennighausen L; Valent P; Decker T; Strobl B; Mueller M; Mustjoki S; Hoelbl-Kovacic A; Sexl V
Leukemia; 2019 Jul; 33(7):1583-1597. PubMed ID: 30679796
[TBL] [Abstract][Full Text] [Related]
3. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML).
Scherr M; Chaturvedi A; Battmer K; Dallmann I; Schultheis B; Ganser A; Eder M
Blood; 2006 Apr; 107(8):3279-87. PubMed ID: 16278304
[TBL] [Abstract][Full Text] [Related]
4. Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity.
Jacobberger JW; Sramkoski RM; Frisa PS; Ye PP; Gottlieb MA; Hedley DW; Shankey TV; Smith BL; Paniagua M; Goolsby CL
Cytometry A; 2003 Aug; 54(2):75-88. PubMed ID: 12879454
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
Hantschel O; Warsch W; Eckelhart E; Kaupe I; Grebien F; Wagner KU; Superti-Furga G; Sexl V
Nat Chem Biol; 2012 Jan; 8(3):285-93. PubMed ID: 22286129
[TBL] [Abstract][Full Text] [Related]
6. Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction.
Fahrenkamp D; de Leur HS; Küster A; Chatain N; Müller-Newen G
Cell Commun Signal; 2015 Feb; 13():10. PubMed ID: 25885255
[TBL] [Abstract][Full Text] [Related]
7. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.
Casetti L; Martin-Lannerée S; Najjar I; Plo I; Augé S; Roy L; Chomel JC; Lauret E; Turhan AG; Dusanter-Fourt I
Cancer Res; 2013 Apr; 73(7):2052-8. PubMed ID: 23400594
[TBL] [Abstract][Full Text] [Related]
8. Thymoquinone Induces Downregulation of BCR-ABL/JAK/STAT Pathway and Apoptosis in K562 Leukemia Cells.
Al-Rawashde FA; Wan Taib WR; Ismail I; Johan MF; Al-Wajeeh AS; Al-Jamal HAN
Asian Pac J Cancer Prev; 2021 Dec; 22(12):3959-3965. PubMed ID: 34967577
[TBL] [Abstract][Full Text] [Related]
9. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
Carlesso N; Frank DA; Griffin JD
J Exp Med; 1996 Mar; 183(3):811-20. PubMed ID: 8642285
[TBL] [Abstract][Full Text] [Related]
10. Comparison between molecularly defined and conventional therapeutics in a conditional BCR-ABL cell culture model.
Chaturvedi A; Battmer K; Schaefer D; Ganser A; Eder M; Scherr M
Oligonucleotides; 2007; 17(1):22-34. PubMed ID: 17461760
[TBL] [Abstract][Full Text] [Related]
11. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.
Chatain N; Ziegler P; Fahrenkamp D; Jost E; Moriggl R; Schmitz-Van de Leur H; Müller-Newen G
Oncogene; 2013 Aug; 32(31):3587-97. PubMed ID: 22926520
[TBL] [Abstract][Full Text] [Related]
12. Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes.
Nishihara T; Miura Y; Tohyama Y; Mizutani C; Hishita T; Ichiyama S; Uchiyama T; Tohyama K
Int J Hematol; 2003 Oct; 78(3):233-40. PubMed ID: 14604282
[TBL] [Abstract][Full Text] [Related]
13. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
[TBL] [Abstract][Full Text] [Related]
14. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism.
Fernández de Mattos S; Essafi A; Soeiro I; Pietersen AM; Birkenkamp KU; Edwards CS; Martino A; Nelson BH; Francis JM; Jones MC; Brosens JJ; Coffer PJ; Lam EW
Mol Cell Biol; 2004 Nov; 24(22):10058-71. PubMed ID: 15509806
[TBL] [Abstract][Full Text] [Related]
15. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.
Nieborowska-Skorska M; Wasik MA; Slupianek A; Salomoni P; Kitamura T; Calabretta B; Skorski T
J Exp Med; 1999 Apr; 189(8):1229-42. PubMed ID: 10209040
[TBL] [Abstract][Full Text] [Related]
16. RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells.
Futami M; Hatano T; Soda Y; Kobayashi S; Miyagishi M; Tojo A
Leukemia; 2008 Jun; 22(6):1131-8. PubMed ID: 18368071
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia.
Waight JD; Banik D; Griffiths EA; Nemeth MJ; Abrams SI
J Biol Chem; 2014 May; 289(22):15642-52. PubMed ID: 24753251
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor.
Tao WJ; Lin H; Sun T; Samanta AK; Arlinghaus R
Oncogene; 2008 May; 27(22):3194-200. PubMed ID: 18071309
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Dai Y; Rahmani M; Pei XY; Dent P; Grant S
Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
[TBL] [Abstract][Full Text] [Related]
20. Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.
Liao Z; Gu L; Vergalli J; Mariani SA; De Dominici M; Lokareddy RK; Dagvadorj A; Purushottamachar P; McCue PA; Trabulsi E; Lallas CD; Gupta S; Ellsworth E; Blackmon S; Ertel A; Fortina P; Leiby B; Xia G; Rui H; Hoang DT; Gomella LG; Cingolani G; Njar V; Pattabiraman N; Calabretta B; Nevalainen MT
Mol Cancer Ther; 2015 Aug; 14(8):1777-93. PubMed ID: 26026053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
